Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak


Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the open-label clinical trial.

WASHINGTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- In continued collaboration with Rwanda to address the Marburg virus outbreak, the Sabin Vaccine Institute has dispatched approximately 1,000 additional investigational vaccine doses for a randomized clinical trial arm within the ongoing open-label study. More than 1,500 frontline workers have already been vaccinated in Rwanda with the Sabin vaccine.

Under the updated protocol, sponsored by the Rwanda Biomedical Center, approximately 1,000 at-risk individuals, including mine workers, will receive Sabin’s single-dose investigational vaccine in a 1-to-1 randomization. Half will receive the vaccine immediately, and the other half 21 days later to align with the end of the disease incubation period.

Genomic sequencing of the index case (first identified case in an infectious disease outbreak) in Rwanda suggests a zoonotic origin, with strains similar to those found in fruit bats in a mine.

The new trial arm will assess safety, immunogenicity, and efficacy. Pending a request from Rwandan officials and authorization from the U.S. Administration for Strategic Response and Preparedness, Sabin plans to supply additional vaccines for this portion of the trial.

“As Rwandan health officials determined, the most expeditious and effective way to reach this new group of people impacted by the outbreak is to adapt the current protocol,” says Sabin CEO Amy Finan. “While this vaccine is still investigational, our mission is to ensure that knowledge can move swiftly from research to real-world solutions, with scientific rigor and safety as our highest priorities.”

At a news conference today about the Marburg outbreak, Rwanda minister of state for health Yvan Butera also addressed the need for more vaccine doses. Since the outbreak began, Sabin has been working directly with Rwandan officials and partners to mount a coordinated response.

As in previous outbreaks, Sabin continues to collaborate closely with its contract manufacturer, ReiThera, to prepare and ship the vialed doses to Rwanda.

Over 1,700 vaccines have already been delivered to Rwanda, with the first shipment of doses arriving just nine days after the outbreak was declared on September 27. The initial part of the trial focused largely on health workers, a group that suffered the most casualties in this outbreak.

Rwanda has confirmed 66 Marburg cases in what is one of the largest recorded outbreaks of the disease. Case numbers declined sharply within two weeks, with 15 deaths reported so far. The case-fatality rate, approximately 23%, remains significantly lower than previous outbreaks, which have seen mortality rates as high as 88%.

Designed to prevent illness before exposure to the virus, Sabin’s Marburg vaccine has not yet been proven to have clinical benefit for recipients of the vaccine. The candidate is currently in Phase 2 trials in Uganda and Kenya with no safety concerns reported to date. In non-human primates, it has demonstrated rapid immunity within one week, and in Phase 1 trials, it has shown safety and immunogenicity in humans.

Marburg virus disease remains a serious threat, with a high case fatality rate, and no approved vaccines currently available. Symptoms typically emerge between two and 21 days after infection.

Since 2019, Sabin has been at the forefront of advancing vaccines for filoviruses based on the cAd3 platform. Interim results from the Marburg trial are expected next year, with a U.S.-based trial planned for 2025. Sabin is also a key partner in MARVAC, a WHO-coordinated effort promoting global collaboration in Marburg vaccine development.

Sabin’s development program, which includes clinical trials and manufacturing of clinical trial material that have been leveraged for this current outbreak, is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi-year contracts. To date, BARDA has obligated $235 million to Sabin for advancing vaccine research and development against Sudan ebolavirus and Marburg virus diseases.

In addition to BARDA and Rwanda’s government, Sabin is grateful for all the organizations including CEPI, GSK, IQVIA, kENUP Africa, National Institutes of Health’s Vaccine Research Center, PPD, WHO, and World Courier who have contributed to our past and current efforts.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f38d0939-533d-4fea-8d71-882be4461b28


Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak

THỦ THUẬT HAY

Hướng dẫn tải Video YouTube về máy tính không cần phần mềm

Hôm nay Download.com.vn sẽ giới thiệu cho các bạn giải pháp mới không cần sử dụng bất kỳ phần mềm hỗ trợ nào cũng có thể dễ dàng tải Video YouTube về máy thưởng thức được.

12 tiện ích mở rộng mà “dân nghiện” Facebook cần phải có

Facebook hiện nay được xem là một phần không thể thiếu trong nhịp sống hiện đại của giới trẻ hiện nay. Và người dùng có thể truy cập Facebook bằng rất nhiều cách nhưng trải nghiệm trên máy tính vẫn được xem là tốt hơn

4 cách sửa lỗi DF-DLA-15 trong quá trình tải ứng dụng trên Play Store

Trong quá trình tải ứng dụng từ Play Store về thiết bị Android, một số người dùng phản ánh lại rằng họ khong thể tải được ứng dụng và trên màn hình thiết bị xuất hiện thông báo lỗi “Can't be Downloaded. Try again, and

Bitdefender TrafficLight: add-on bảo vệ người dùng cho trình duyệt Firefox

Bảo vệ an toàn khi sử dụng trình duyệt là điều mà người dùng cực kỳ quan tâm. Mới đây, Bitdefender cung cấp add-on cho trình duyệt Firefox để bảo vệ người dùng với tên gọi Bitdefender TrafficLight. Các bạn hãy cài đặt

Top 5 ứng dụng hát Karaoke tuyệt vời dành cho Andoird

Bạn sử dụng điện thoại thông minh cho tất cả mọi thứ, vậy tại sao không sử dụng nó để hát Karaoke? Hát những bài hát bạn yêu thích, thêm hiệu ứng cho giọng hát và thậm chí còn có nhóm hát bè. Vậy nên bài viết dưới đây

ĐÁNH GIÁ NHANH

Đánh giá camera Moto Z2 Play: điện thoại có giống bạn "ảo" và "deep" hơn không?

Camera sau của máy so với thế hệ trước dù bị giảm từ 16MP xuống chỉ còn 12MP nhưng lại được thêm khả năng lấy nét tự động theo điểm ảnh và lấy nét tự động bằng laser cùng vơi việc tăng khẩu độ từ f/2.0 lên f/1.7 giúp

Đánh giá pin Asus Zenfone Max Plus M1: Thời lượng thực tế chưa ấn tượng so với dung lượng

Asus Zenfone Max Plus M1 là chiếc smartphone có cái tên khá dài, liệu thời lượng sử dụng pin của máy có dài giống như tên của sản phẩm này hay không?

Đánh giá chiếc Chromebook HP 13: ngoại hình khỏi chê, pin trâu

Hiện nay, HP là một trong những nhà sản xuất Chromebook tốt nhất trên thị trường hiện nay. Mới đây, hãng đã tung ra một dòng Chromebook mới, hứa hẹn sẽ là một sản phẩm dẫn đầu trong dòng notebook chạy Chrome OS. Bài...